Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes

H M Ockenfels1, G Nussbaum, T Schultewolter

  • 1Department of Dermatology, University of Essen, Germany.

Insights

FK506 and dithranol reduce tyrosine phosphorylation in keratinocytes, potentially improving psoriasis. Cyclosporin A had no effect, and protein kinase C activation alone doesn't fully explain these drug effects.

Area of Science:

  • Dermatology
  • Biochemistry
  • Cell Biology

Background:

  • Protein tyrosine kinases (PTKs) regulate cell growth and differentiation.
  • Abnormal PTK activity, particularly elevated EGF receptors, is linked to psoriatic hyperproliferation.
  • Current treatments like cyclosporin A, FK506, and dithranol show efficacy in psoriasis.

Purpose of the Study:

  • To investigate the impact of cyclosporin A, FK506, and dithranol on tyrosine phosphorylation in HaCaT keratinocytes.
  • To explore the role of protein kinase C (PKC) in mediating the effects of these drugs.

Main Methods:

  • Utilized HaCaT keratinocytes as a model for hyperproliferative epidermis.
  • Assessed cellular phosphotyrosine levels after treatment with cyclosporin A, FK506, and dithranol.
  • Investigated drug effects in combination with a selective PKC inhibitor (Ro 31-8220).

Main Results:

  • Cyclosporin A showed no significant effect on tyrosine phosphorylation.
  • FK506 and dithranol markedly reduced tyrosine phosphorylation in HaCaT keratinocytes.
  • Inhibition of PKC partially reversed the FK506-induced reduction in phosphotyrosine, but not to baseline levels.

Conclusions:

  • FK506 and dithranol decrease tyrosine phosphorylation in keratinocytes, suggesting a mechanism for their therapeutic effect in psoriasis.
  • PKC activation alone is not solely responsible for the observed reduction in phosphotyrosine levels.
  • Further research is needed to fully elucidate the pathways involved in drug-induced modulation of PTK activity in psoriasis.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...